Abstract
Magnetic Resonance Imaging (MRI) has become the most useful para-clinical tool to detect (subclinical) disease activity in order to evaluate treatment response and inform clinical decisions about Disease Modifying Treatment (DMT) in people with Multiple Sclerosis (pwMS). However, current evaluation of brain MRI scans, in a clinical setting, requires visual inspection, the sensitivity of which is degraded by multiple human and technological factors. AI-derived software for medical image quantification offer gains in efficiency, accuracy, clinical relevance, reduced subjectivity, and have the potential to allow timely therapy decisions which can improve patient’s outcome. The aim of this research is to provide an initial evaluation of the cost-effectiveness of AI-assisted radiological assessment in the MS clinical decision-making pathway in the UK using a health-care perspective.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
